Prothena Corp Public (PRTA) EBT (2012 - 2026)
Prothena Corp Public (PRTA) posted quarterly EBT of $32.7 million for Q1 2026, up 153.32% year-over-year from $12.9 million in Q1 2025, and up 251.64% quarter-over-quarter from -$21.6 million in Q4 2025.
Prothena Corp Public (PRTA) EBT (2012 - 2026) Analysis & Trends
Prothena Corp Public's EBT history runs 15 years deep, the most recent figure standing at $32.7 million for Q1 2026.
- In Q1 2026, EBT rose 153.32% year-over-year to $32.7 million; the TTM figure through Mar 2026 stood at -$106.7 million (up 7.88% YoY), while the FY2025 annual figure was -$200.8 million, down 55.77% from the prior year.
- EBT for Q1 2026 stood at $32.7 million, up from -$21.6 million in the prior quarter.
- The five-year high for EBT was $64.8 million in Q2 2024, with the low at -$81.0 million in Q2 2025.
- The 5-year median for EBT is -$48.4 million (2022), against an average of -$34.3 million.
- The sharpest annual moves came in 2023 and 2024: EBT slumped 2211.15% in 2023, then surged 210.09% in 2024.
- Prothena Corp Public's EBT stood at $3.3 million in 2022, then plunged by 2211.15% to -$70.6 million in 2023, then gained by 15.74% to -$59.5 million in 2024, then jumped by 63.73% to -$21.6 million in 2025, then soared by 251.64% to $32.7 million in 2026.
- Business Quant data shows PRTA's EBT at $32.7 million in Q1 2026, -$21.6 million in Q4 2025, and -$36.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Prothena Corp Public | 458.45 Mn | 170.25 Mn | - | -18.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -18.58 Mn |
| Mar 31, 2026 | 32.72 Mn |
| Dec 31, 2025 | -21.58 Mn |
| Sep 30, 2025 | -36.91 Mn |
| Jun 30, 2025 | -80.97 Mn |
| Mar 31, 2025 | -61.37 Mn |
| Dec 31, 2024 | -59.50 Mn |
| Sep 30, 2024 | -59.84 Mn |
| Jun 30, 2024 | 64.85 Mn |
| Mar 31, 2024 | -74.44 Mn |
| Dec 31, 2023 | -70.62 Mn |
| Sep 30, 2023 | 18.82 Mn |
| Jun 30, 2023 | -58.90 Mn |
| Mar 31, 2023 | -49.78 Mn |
| Dec 31, 2022 | 3.35 Mn |
| Sep 30, 2022 | -48.42 Mn |
| Jun 30, 2022 | -42.57 Mn |
| Mar 31, 2022 | -37.96 Mn |
| Dec 31, 2021 | -33.10 Mn |
| Sep 30, 2021 | 109.20 Mn |